Taiko Pharmaceutical Co Ltd
TSE:4574
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Taiko Pharmaceutical Co Ltd
Total Equity
Taiko Pharmaceutical Co Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Taiko Pharmaceutical Co Ltd
TSE:4574
|
Total Equity
¥8.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-4%
|
|
|
Hoya Corp
TSE:7741
|
Total Equity
¥1T
|
CAGR 3-Years
8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
H
|
Hogy Medical Co Ltd
TSE:3593
|
Total Equity
¥74.5B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-2%
|
|
|
A
|
Asahi Intecc Co Ltd
TSE:7747
|
Total Equity
¥157.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
16%
|
CAGR 10-Years
17%
|
|
|
Mani Inc
TSE:7730
|
Total Equity
¥56.7B
|
CAGR 3-Years
7%
|
CAGR 5-Years
9%
|
CAGR 10-Years
7%
|
|
|
Nipro Corp
TSE:8086
|
Total Equity
¥255.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
11%
|
CAGR 10-Years
4%
|
|
Taiko Pharmaceutical Co Ltd
Glance View
Taiko Pharmaceutical Co., Ltd. engages in the manufacture and sale of general medications particularly non-prescription gastrointestinal drugs and designated quasi drugs. The company is headquartered in Osaka, Osaka-Fu and currently employs 264 full-time employees. The company went IPO on 2009-03-18. The firm is engaged in three business segments. The Pharmaceutical Product segment is engaged in the manufacturing, sales and export of gastrointestinal drugs under the name SEIROGAN, SEIROGAN TOI-A (sugar coated tablet) and PISHUT. The Infection Control segment is engaged in the planning, development and sales of infection control products, which apply proprietary technique regarding chlorine dioxide gas. The Others segment is engaged in the manufacturing and sales of bath liquid, soap and gardening pyroligneous acid.
See Also
What is Taiko Pharmaceutical Co Ltd's Total Equity?
Total Equity
8.5B
JPY
Based on the financial report for Dec 31, 2025, Taiko Pharmaceutical Co Ltd's Total Equity amounts to 8.5B JPY.
What is Taiko Pharmaceutical Co Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
-4%
Over the last year, the Total Equity growth was 7%. The average annual Total Equity growth rates for Taiko Pharmaceutical Co Ltd have been 2% over the past three years , -18% over the past five years , and -4% over the past ten years .
